Download the White Paper to learn more.
For emerging biopharma companies, reaching critical early milestones like IND clearance and first-in-human trials can mean the difference between securing next-round funding or exhausting capital. Traditional upstream development approaches often extend timelines through trial-and-error vector design, manual optimization and sequential workflows—raising the risk of delays that can derail promising programs.
Patheon’s Path to IND platform integrates next-generation technologies that accelerate biologics from discovery to clinic while maintaining quality and regulatory compliance. By combining AI-driven vector design, advanced transposase technology, high-throughput clone selection and intensified fed-batch processes, the platform delivers titer levels up to 8 g/L and scales recombinant antibodies to FIH trials in 9 to 14 months.*
Download the white paper to discover:
- How AI/ML-enabled vector construction eliminates weeks of trial-and-error design work
- Why transposase and afucosylation technologies accelerate cell line development while improving product quality
- How high-throughput single-cell cloning achieved 93% efficiency with 100% monoclonality for complex bispecifics
Real-world results showing 60% titer improvements through optimized fed-batch intensification
Offered Free by: Thermo Fisher Scientific
See All Resources from: Thermo Fisher Scientific
